Stocks · News reference
Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $74
Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $78 to $74.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
'Legend Naming Novartis Executive as CEO' - Wall Street Journal
https://www.wsj.com/health/pharma/legend-naming-novartis-executive-as-ceo-6a79fa0c
Legend Biotech To Present Data For Its CARTITUDE-2 Trial Of CARVYKTI At 23rd International Myeloma Society Annual Meeting
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that data from CARTITUDE-2 and real-world evidence will be presented at the 23rd International Myeloma Society